Actively Recruiting
Entresto Tablets and Granules for Pediatric Specified Drug-use Survey (Pediatric Chronic Heart Failure)
Led by Novartis Pharmaceuticals · Updated on 2026-04-13
30
Participants Needed
28
Research Sites
153 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is multicenter, single-arm, non-interventional, centrally enrolled specified drug-use survey to investigate the safety of Entresto Tablets or Entresto Granules for Pediatric in pediatric patients with chronic heart failure in actual clinical settings for up to 52 weeks after administration.
CONDITIONS
Official Title
Entresto Tablets and Granules for Pediatric Specified Drug-use Survey (Pediatric Chronic Heart Failure)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Written informed consent by a legally acceptable representative must be obtained before the start of treatment with Entresto.
- Patients who received Entresto for the first time under the indication of chronic heart failure
- Pediatric patients aged 1 to < 18 years old at the start of treatment with Entresto
You will not qualify if you...
- Patients who have received drugs containing the same ingredient as Entresto (including investigational products and drugs for post-marketing clinical study)
- Patients with a history of hypersensitivity to any ingredients of Entresto
- Patients currently under treatment with angiotensin-converting enzyme inhibitors or within 36 hours of discontinuation of such treatment
- Patients with a history of angioedema (including angioedema due to angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors, hereditary angioedema, acquired angioedema, and idiopathic angioedema)
- Patients with diabetes mellitus under treatment with aliskiren fumarate (except those with markedly poorly controlled blood pressure despite other antihypertensive therapies)
- Patients with severe hepatic impairment (Child-Pugh class C)
- Pregnant women or women who may be pregnant
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 28 locations
1
Novartis Investigative Site
Ōbu, Aichi-ken, Japan, 474 8710
Actively Recruiting
2
Novartis Investigative Site
Toyoake, Aichi-ken, Japan, 4701192
Actively Recruiting
3
Novartis Investigative Site
Kurume, Fukuoka, Japan, 830-0011
Actively Recruiting
4
Novartis Investigative Site
Kurume, Fukuoka, Japan, 830-8543
Actively Recruiting
5
Novartis Investigative Site
Sapporo, Hokkaido, Japan, 060-8648
Actively Recruiting
6
Novartis Investigative Site
Tsukuba, Ibaraki, Japan, 3058576
Actively Recruiting
7
Novartis Investigative Site
Kawasaki, Kanagawa, Japan, 2168511
Actively Recruiting
8
Novartis Investigative Site
Yokohama, Kanagawa-ku, Japan, 236-0004
Actively Recruiting
9
Novartis Investigative Site
Tsu, Mie-ken, Japan, 514-8507
Actively Recruiting
10
Novartis Investigative Site
Nagasaki, Nagasaki, Japan, 852-8501
Actively Recruiting
11
Novartis Investigative Site
Ōmura, Nagasaki, Japan, 856-8562
Actively Recruiting
12
Novartis Investigative Site
Hidaka, Saitama, Japan, 350-1298
Actively Recruiting
13
Novartis Investigative Site
Saitama, Saitama, Japan, 330-8777
Actively Recruiting
14
Novartis Investigative Site
Hamamatsu, Shizuoka, Japan, 430-8558
Actively Recruiting
15
Novartis Investigative Site
Bunkyo Ku, Tokyo, Japan, 113-8655
Actively Recruiting
16
Novartis Investigative Site
Bunkyo Ku, Tokyo, Japan, 1138431
Actively Recruiting
17
Novartis Investigative Site
Bunkyo-ku, Tokyo, Japan, 113-8603
Actively Recruiting
18
Novartis Investigative Site
Fuchū, Tokyo, Japan, 183-0003
Actively Recruiting
19
Novartis Investigative Site
Fuchū, Tokyo, Japan, 1838561
Actively Recruiting
20
Novartis Investigative Site
Ōta-ku, Tokyo, Japan, 143 8541
Actively Recruiting
21
Novartis Investigative Site
Setagaya-ku, Tokyo, Japan, 1578535
Actively Recruiting
22
Novartis Investigative Site
Shinagawa-ku, Tokyo, Japan, 1428666
Actively Recruiting
23
Novartis Investigative Site
Shinjuku Ku, Tokyo, Japan, 1628666
Actively Recruiting
24
Novartis Investigative Site
Toyama, Toyama, Japan, 9300194
Actively Recruiting
25
Novartis Investigative Site
Akita, Japan, 010-8543
Actively Recruiting
26
Novartis Investigative Site
Fukuoka, Japan, 8128582
Active, Not Recruiting
27
Novartis Investigative Site
Kumamoto, Japan, 862-8505
Completed
28
Novartis Investigative Site
Okayama, Japan, 7008558
Actively Recruiting
Research Team
N
Novartis Pharmaceuticals
CONTACT
N
Novartis Pharmaceuticals
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here